Alnylam Going After Alexion's Soliris In PNH, Eyes Roche In Hemophilia
This article was originally published in The Pink Sheet Daily
Executive Summary
At an investor day, the RNAi firm outlined Phase I programs in paroxysmal nocturnal hemoglobinuria, hemophilia and hepatic porphyria, and said it is using a de-risked drug development methodology.
You may also be interested in...
Alnylam Ramps Up Commercial Planning For Givosiran Based On Phase III Data
The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.
Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”